ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma

Abstract Primary liver cancer is one of the most frequently diagnosed and deadliest cancers. Zinc finger E-box binding homeobox 1 (ZEB1) is negative prognostic factor in liver cancer by promoting therapy resistance and tumorigenesis. Interfering in pathways of cellular metabolism emerges as a potent...

Full description

Saved in:
Bibliographic Details
Main Authors: H. Freudenstein, M. Strecker, S. Gylstorff, W. Shi, M. Boettcher, S. Medunjanin, C. Catapano, C. Siba, C. Wex, T. Wartmann, A. Y. Sanin, M. Franz, J. Arend, D. Mougiakakos, M. Pech, R. S. Croner, U. D. Kahlert, F. Stelter
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Hepatocellular carcinoma
ZEB1
EMT
Mitochondrial metabolism
Sorafenib
Mdivi-1
Online Access:https://doi.org/10.1038/s41598-025-16379-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-16379-6

Similar Items